罗氏收购的候选药物CT-388在早期肥胖症试验中表现出积极的减肥效果，激发了市场的兴趣。 Roche's acquired drug candidate, CT-388, demonstrated positive weight loss results in early-stage obesity trial, boosting market interest.

罗氏公司从 Carmot Therapeutics 收购的候选药物在针对肥胖成人的早期临床试验中显示出减肥的积极效果，此后罗氏公司股价上涨。 Roche shares rose after its drug candidate, acquired from Carmot Therapeutics, showed positive results for weight loss in an early-stage clinical trial in adults with obesity. CT-388 药物与安慰剂相比，可显著减轻体重，这增加了市场对肥胖症治疗药物的兴趣，目前该领域由诺和诺德和礼来主导，各大制药集团都在寻求进入这个价值 1000 亿美元的市场。 The drug, CT-388, led to significant weight loss compared to a placebo, adding to the market interest for obesity treatments, currently dominated by Novo Nordisk and Eli Lilly, as pharma groups seek to tap into the $100bn market.